Top Page
Treatment.com International
(OTC:TRUE)
Treatment.com International (TRUE) vs. S&P 500 (SPY)
Treatment.com International Business Overview & Revenue Model
Treatment.com International Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| -27.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -27.15K | 0.00 | -377.28K | -656.40K | -326.85K | 0.00 | EBIT |
| -4.65M | -2.33M | -3.84M | -13.92M | -2.91M | -672.36K | EBITDA |
| -7.47M | -3.65M | 0.00 | 0.00 | -2.91M | 0.00 | Net Income Common Stockholders |
| -7.52M | -3.72M | -3.70M | -13.84M | -2.91M | -3.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 515.39K | 715.53K | 2.50K | 916.75K | 312.64K | 515.39K | Total Assets |
| 515.39K | 739.31K | 13.67K | 942.51K | 313.20K | 515.39K | Total Debt |
| 0.00 | 442.13K | 566.28K | 0.00 | 0.00 | 0.00 | Net Debt |
| -515.39K | -273.39K | 563.78K | -916.75K | -312.64K | -515.39K | Total Liabilities |
| 165.28K | 1.48M | 2.20M | 832.62K | 576.46K | 165.28K | Stockholders Equity |
| 350.11K | -738.05K | -2.19M | 109.90K | -263.26K | 350.11K |
| Cash Flow | Free Cash Flow | ||||
| -4.13M | -740.08K | -1.46M | -6.29M | -2.01M | -509.71K | Operating Cash Flow |
| -4.13M | -740.08K | -1.46M | -6.29M | -2.01M | -509.71K | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 3.47M | 1.45M | 540.62K | 6.94M | 1.86M | 1.00M |
Treatment.com International Technical Analysis
Treatment.com International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | C$174.35M | ― | -4.48% | ― | -0.69% | 8.08% | |
64 Neutral | C$575.85M | 52.66 | 1.41% | ― | 12.21% | ― | |
60 Neutral | C$152.92M | ― | -23.05% | ― | -3.73% | 32.70% | |
52 Neutral | $5.04B | 3.15 | -44.58% | 2.85% | 16.08% | -0.27% | |
34 Underperform | C$26.10M | ― | ― | -171.18% | 46.80% |
Treatment.com International Corporate Events
Treatment.com AI Inc. has successfully completed the acquisition of Rocket Doctor Inc., a company that empowers doctors to establish virtual practices, thereby enhancing access to medical care. This strategic acquisition is expected to integrate Treatment.com’s AI capabilities, such as the AI Nurse, to improve patient triage and onboarding, potentially boosting the company’s market position and offering proof of concept for future software sales.
Spark’s Take on TSE:TRUE Stock
According to Spark, TipRanks’ AI Analyst, TSE:TRUE is a Underperform.
Treatment.com faces substantial financial issues, including ongoing losses and negative cash flow, which are the primary reasons for its low overall score. Despite some positive corporate events, such as strategic acquisitions and partnerships, these have not yet mitigated the financial difficulties. The technical analysis suggests lackluster momentum, and the valuation metrics highlight the company’s unprofitable status, further weighing down the score.
To see Spark’s full report on TSE:TRUE stock, click here.
Treatment.com AI Inc. has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology Ltd to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and the Far East. The partnership aims to combine Aiyibotong’s CDSS with Treatment’s Global Library of Medicine to enhance patient support and increase market share. This collaboration aligns with the growing investment in digital health in China, expected to reach $45 billion in 2025, and the CDSS market projected to double by 2030. The agreement includes co-marketing efforts and the development of an AI-based CDSS for the global market, leveraging both companies’ technologies and expertise.
Rocket Doctor, a virtual healthcare marketplace associated with Treatment.com AI Inc., is rapidly expanding in Alberta, enhancing healthcare access and supporting physician independence. With over 71,000 Albertans served and a significant increase in both patient visits and physician adoption, Rocket Doctor is addressing the province’s physician shortage. The platform’s unique model supports independent doctors, aligning with Alberta’s healthcare framework and earning high patient satisfaction. As demand grows, Rocket Doctor plans to integrate AI-driven tools and expand its services, positioning itself as a sustainable solution for healthcare accessibility and innovation in Alberta.
Treatment.com AI Inc. has announced an extension of its marketing and investor awareness services with i2i Marketing Group for an additional two months, costing an extra USD$200,000. This extension is part of the company’s efforts to enhance its market presence through digital marketing strategies, potentially impacting its industry positioning by increasing visibility and engagement with stakeholders.
Treatment.com AI Inc. has successfully closed an upsized brokered private placement, raising $3.3 million through the issuance of 6.6 million units. This funding will support the company’s growth plans, including sales, administrative expenses, and software research and development, potentially enhancing its market position and operational capabilities.
Treatment.com AI Inc. has announced a brokered private placement agreement with Ventum Financial Corp. to raise C$3,000,000 through the issuance of 6,000,000 units priced at C$0.50 each. The proceeds from this offering will be used for research and development, sales, and general administrative expenses, potentially strengthening the company’s financial position and supporting its growth in the AI healthcare sector.
Rocket Doctor has been approved as an in-network provider for New York Medicaid, allowing 6.9 million Medicaid beneficiaries to access its virtual healthcare services. This expansion is expected to enhance healthcare access for 35% of New York’s population, reduce emergency room visits, and improve timely specialist referrals. The partnership with EngageWell, supported by a $1 million grant, aims to further enhance virtual care for aging New Yorkers, addressing healthcare disparities and ensuring comprehensive, on-demand medical care.
Treatment.com AI Inc. has announced its acquisition of Rocket Doctor Inc. as part of its strategy to enhance healthcare delivery through AI. The CEOs of both companies discussed the potential of their combined technologies to address inefficiencies in the healthcare sector, aiming to improve patient care and support healthcare providers. This acquisition is expected to strengthen Treatment.com’s market position by integrating Rocket Doctor’s digital health platform with its AI capabilities, potentially impacting stakeholders by offering more comprehensive healthcare solutions.
Treatment.com AI Inc. has announced that its subsidiary, Rocket Doctor, has partnered with a California managed care plan to provide healthcare services to approximately 450,000 Medicaid members. This partnership is expected to enhance healthcare access by offering tele-urgent care, specialty services, and primary care through a virtual care platform, reducing unnecessary emergency room visits and wait times, while generating an anticipated additional annual recurring revenue of approximately US$1.2 million.
Treatment.com AI Inc. has announced a new non-dilutive M&A credit facility of up to $1.5 million to fund expenses related to strategic acquisitions like Rocket Doctor. This facility is intended to support the company’s growth through revenue-boosting acquisitions, enhancing its market position in the healthcare industry by enabling the company to expand its operations without issuing new securities.
Treatment.com AI Inc. has announced a definitive agreement to acquire Rocket Doctor Inc., a digital health company that empowers doctors to establish virtual practices in the U.S. and Canada. This acquisition will enhance Treatment.com’s capabilities by integrating Rocket Doctor’s AI-powered platform, boosting the network to over 300 doctors and increasing services billable value to C$7.1 million. The deal, valued at approximately C$11 million in shares with potential additional consideration based on performance, aims to drive innovation in digital healthcare services across North America, offering a proof of concept for future commercial sales of Treatment’s software.